{"id":"https://openalex.org/W2577901327","doi":"https://doi.org/10.1182/blood.v116.21.3082.3082","title":"Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis","display_name":"Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2577901327","doi":"https://doi.org/10.1182/blood.v116.21.3082.3082","mag":"2577901327"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.3082.3082","doi":"https://doi.org/10.1182/blood.v116.21.3082.3082","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3082.3082","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010962133","display_name":"H. Joachim Deeg","orcid":"https://orcid.org/0000-0002-4426-9023","observed_orcids":["https://orcid.org/0000-0002-4426-9023"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Joachim Deeg","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA,","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060015628","display_name":"Olatoyosi M. Odenike","orcid":"https://orcid.org/0000-0002-4027-4124","observed_orcids":["https://orcid.org/0000-0002-4027-4124"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olatoyosi Odenike","raw_affiliation_strings":["hematology/Oncology, The University of Chicago Medical Ctr., Chicago, IL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"hematology/Oncology, The University of Chicago Medical Ctr., Chicago, IL, USA,","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111972500","display_name":"Joy Zhu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Joy Zhu","raw_affiliation_strings":["Global Clinical Development, S*BIO, Redwood City, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development, S*BIO, Redwood City, CA, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084290698","display_name":"Zeev E. Estrov","orcid":"https://orcid.org/0000-0002-1623-3613","observed_orcids":["https://orcid.org/0000-0002-1623-3613"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zeev Estrov","raw_affiliation_strings":["Leukemia, MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074629157","display_name":"Bart Lee Scott","orcid":"https://orcid.org/0000-0001-9620-7839","observed_orcids":["https://orcid.org/0000-0001-9620-7839"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bart Lee Scott","raw_affiliation_strings":["Department of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038307470","display_name":"Deborah Ann Thomas","orcid":"https://orcid.org/0000-0002-2656-343X","observed_orcids":["https://orcid.org/0000-0002-2656-343X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah A Thomas","raw_affiliation_strings":["Leukemia, MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5111972500"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":4.1426,"has_fulltext":false,"cited_by_count":37,"citation_normalized_percentile":{"value":0.94251019,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"116","issue":"21","first_page":"3082","last_page":"3082"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.9589999914169312},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.8999999761581421},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9769999980926514},{"id":"https://openalex.org/keywords/stat3-phosphorylation","display_name":"STAT3 phosphorylation","score":0.7710000276565552},{"id":"https://openalex.org/keywords/stat5-phosphorylation","display_name":"STAT5 phosphorylation","score":0.9729999899864197},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.6520000100135803},{"id":"https://openalex.org/keywords/oral-jak-inhibitor","display_name":"oral JAK inhibitor","score":0.5019999742507935},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.5090000033378601},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8100000023841858},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.37599998712539673}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7860302925109863},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5950585603713989},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5459162592887878},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.5208899974822998},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.5061466097831726},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.4457658529281616},{"id":"https://openalex.org/C112392421","wikidata":"https://www.wikidata.org/wiki/Q903451","display_name":"Janus kinase","level":3,"score":0.44232290983200073},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.440046489238739},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38446158170700073},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.25710421800613403},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.19972822070121765},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.1351282000541687},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13492602109909058},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.11751267313957214},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09997937083244324}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v116.21.3082.3082","doi":"https://doi.org/10.1182/blood.v116.21.3082.3082","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.3082.3082","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9789000153541565}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2253804938","https://openalex.org/W2566841041","https://openalex.org/W2591579771","https://openalex.org/W2053824759","https://openalex.org/W1973160387","https://openalex.org/W2522065755","https://openalex.org/W2551347316","https://openalex.org/W2047018224","https://openalex.org/W2588005189","https://openalex.org/W2558808839"],"abstract_inverted_index":{"Abstract":[0,1],"3082":[2],"Mutation":[3],"of":[4,27,37,81,90,94,101,114,125,145,183,188,201,210,259,399,487,523,551],"Janus":[5],"Associated":[6],"Kinase":[7],"2":[8,165,186,389,521],"(JAK2)":[9],"at":[10,121,137,420,518],"amino":[11],"acid":[12],"617":[13],"and":[14,44,61,64,105,110,116,131,153,175,177,204,208,230,289,294,299,305,347,401,445,449,467,474,502,510],"the":[15,25,77,91,102,132,146,149,162,169,184,189,194,199,206,239,246,325,367,483,519],"resulting":[16],"constitutively":[17],"active":[18],"JAK2V617F":[19,46],"enzyme":[20],"has":[21,489,514],"been":[22,228,254,272,340,440,490,515],"linked":[23],"to":[24,59,192,344,350,355,387,404],"pathogenesis":[26],"myeloproliferative":[28],"neoplasms":[29],"(MPN).":[30],"SB1518":[31,126,213,492,513],"is":[32,53,73,373],"a":[33,334,475],"potent":[34],"ATP-competitive":[35],"inhibitor":[36],"both":[38,443,500],"JAK2":[39,56,152],"(IC50":[40,48,70],"=":[41,49,71],"23":[42,360],"nM)":[43,51],"its":[45],"mutant":[47],"19":[50],"that":[52],"selective":[54],"for":[55,148,234,393,397,418,458,477],"inhibition":[57,69,85],"compared":[58],"JAK1":[60],"JAK3":[62],"(58":[63],"24":[65,450],"fold,":[66],"respectively).":[67],"Flt3":[68],"22nM)":[72],"also":[74],"observed.":[75,491],"In":[76],"phase":[78],"1":[79,385,392,402],"portion":[80,187],"this":[82],"study,":[83,413],"target":[84,150],"was":[86,119,159,250,263],"evaluated":[87,430,472],"by":[88,99,423,431,442],"assessment":[89],"activation":[92],"state":[93,134],"JAK-STAT":[95],"pathways":[96],"as":[97,161,333],"measured":[98],"phosphorylation":[100,118],"STAT3,":[103],"STAT5":[104,117],"JAK":[106],"proteins":[107],"in":[108,143,173,220,330,436,479,499,505,526],"PBMCs":[109],"whole":[111],"blood.":[112],"Inhibition":[113],"STAT3":[115],"observed":[120,441],"all":[122,138,459],"dose":[123,139,166,323,522],"levels":[124,140],"from":[127],"100\u2013600":[128],"mg":[129,156,212],"daily,":[130],"steady":[133],"plasma":[135],"concentrations":[136],"were":[141,307,353,416],"well":[142,516],"excess":[144],"IC50":[147],"enzymes":[151],"FLT3.":[154],"400":[155,211],"orally":[157,216],"daily":[158,218,525],"selected":[160],"recommended":[163],"Phase":[164,185,520],"based":[167],"on":[168,364,370,412,547],"response":[170,197,203,400,419,429],"rate":[171],"(reduction":[172],"splenomegaly)":[174],"safety":[176,207],"tolerability":[178,209],"with":[179,225,241,497,507,528],"long-term":[180],"administration.":[181],"Objectives":[182],"study":[190,240,319,356,365,371,383],"are":[191,232,470],"determine":[193],"spleen":[195,202,437,452],"reduction":[196,453,478],"rate,":[198],"duration":[200,369],"assess":[205],"when":[214],"administered":[215],"once":[217],"continuously":[219],"28-day":[221],"cycles.":[222],"Thirty-three":[223],"patients":[224,237,313,361,380,407,415,426,506,527],"PMF":[226],"have":[227,271,339,381,408,427,439],"enrolled":[229],"32":[231],"evaluable":[233,417],"safety.":[235],"All":[236,252],"entered":[238],"splenomegaly:":[242],"median":[243,257,368],"span":[244],"below":[245],"left":[247],"costal":[248],"margin":[249],"18cm.":[251],"had":[253,428],"previously":[255],"treated:":[256],"number":[258],"prior":[260],"systemic":[261],"therapies":[262],"1.":[264],"The":[265],"most":[266],"common":[267],"related":[268,354],"adverse":[269,315],"events":[270,316],"diarrhea":[273],"81%":[274],"(6%":[275],"G3),":[276],"nausea":[277],"41%":[278],"(all":[279,283,287,297],"G1,2),":[280,284],"vomiting":[281],"22%":[282],"fatigue":[285,466],"9%":[286],"G1,2)":[288,298],"abdominal":[290,468],"pain,":[291,462],"extremity":[292],"pain":[293,469],"insomnia":[295],"6%":[296,301],"rash":[300],"(3%":[302],"G3).":[303],"Neutropenia":[304],"thrombocytopenia":[306],"uncommon":[308],"(no":[309],"G3/4":[310],"events).":[311],"Eighteen":[312],"experienced":[314],"requiring":[317],"either":[318],"drug":[320,372],"interruption":[321],"and/or":[322],"reduction,":[324],"majority":[326],"reported":[327],"GI":[328],"symptoms,":[329],"particular":[331],"diarrhea,":[332],"contributing":[335],"factor.":[336],"Three":[337],"deaths":[338],"reported,":[341],"two":[342],"due":[343,349,386,403],"disease":[345,394],"progression":[346],"one":[348],"hemorrhage,":[351],"none":[352],"drug.":[357],"To":[358],"date,":[359],"(69.9%)":[362],"remain":[363],"drug;":[366],"3.7":[374],"months":[375],"(range":[376],"0.4\u20134.6":[377],"months).":[378],"Ten":[379],"discontinued":[382],"drug,":[384],"AE,":[388],"withdrew":[390],"consent,":[391],"progression,":[395],"5":[396],"lack":[398],"death.":[405],"25":[406],"completed":[409],"12":[410,421,485],"weeks":[411,422,486],"17/25":[414],"MRI.":[424],"Thirty":[425],"physical":[432,446],"examination.":[433],"Significant":[434],"reductions":[435,498],"size":[438],"MRI":[444],"exam.":[447],"Twelve":[448],"week":[451],"data":[454],"will":[455],"be":[456],"presented":[457],"patients.":[460],"Bone":[461],"night":[463],"sweats,":[464],"pruritus,":[465],"being":[471],"monthly":[473],"trend":[476],"MF-associated":[480,503],"symptoms":[481,504],"within":[482],"first":[484],"treatment":[488],"shows":[493],"promising":[494],"clinical":[495],"efficacy":[496],"splenomegaly":[501],"symptomatic":[508],"MF":[509],"baseline":[511],"splenomegaly.":[512],"tolerated":[517],"400mg":[524],"CIMF.":[529],"Disclosures:":[530],"Verstovsek:":[531],"Incyte":[532],"Corporation:":[533,537,543],"Research":[534,538,556,564],"Funding.":[535,539,557,565],"Odenike:Genzyme":[536],"Zhu:S*BIO:":[540],"Employment.":[541],"Kantarjian:Genzyme":[542],"Consultancy,":[544],"Honoraria,":[545],"Membership":[546],"an":[548],"entity's":[549],"Board":[550],"Directors":[552],"or":[553],"advisory":[554],"committees,":[555],"Thomas:Novartis:":[558],"Honoraria;":[559,561],"Bristol-Meyer-Squibb:":[560],"Pfizer:;":[562],"Amgen:":[563]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2017-01-26T00:00:00"}